Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John-John B Schnog

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|March 26, 2026
Sacituzumab Govitecan in Advanced Triple-Negative Breast CancerTimothée Olivier, John-John B Schnog
British Journal of Haematology|June 29, 2006
Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell diseaseAshley J Duits, Tati Rodriguez, John-John B Schnog, et al.
American Journal of Hematology|May 29, 2025
Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is UndefinedRuben Van Dijck, Zoran Erjavec, John-John B Schnog
British Journal of Haematology|April 24, 2026
A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myelomaJohn-John B Schnog, Zoran Erjavec, Ruben Van Dijck
Nederlands Tijdschrift Voor Geneeskunde|October 27, 2022
[Financial conflict of interest and anti-cancer drugs: Why the NTVG's stance to exclude pharma-advertisement is of importance.]John-John B Schnog, Michael J Samson, Ashley J Duits
The New England Journal of Medicine|September 21, 2022
Trastuzumab Deruxtecan in HER2-Low Breast CancerJohn-John B Schnog, Michael J Samson, Ashley J Duits
British Journal of Haematology|January 12, 2023
An analytical view of the BJH publication of 'a clinician's view of voxelotor'John-John B Schnog, Michael J Samson, Ashley J Duits
Lancet Regional Health. Americas|February 13, 2023
Contemporary oncology trials, drug approvals and the physician-patient relationshipJohn-John B Schnog, Michael J Samson, Ashley J Duits
Cancer|February 6, 2025
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?Bart M F Penninx, Michael J Samson, John-John B Schnog
American Journal of Hematology|December 24, 2009
Letter in response to: "Pulmonary thrombi are not detected by 3D magnetic resonance angiography in adults with sickle cell anemia and an elevated triscuspid regurgitant jet velocity"Eduard J Van Beers, Bart J Biemond, John-John B Schnog, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|March 26, 2026
Sacituzumab Govitecan in Advanced Triple-Negative Breast CancerTimothée Olivier, John-John B Schnog
British Journal of Haematology|June 29, 2006
Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell diseaseAshley J Duits, Tati Rodriguez, John-John B Schnog, et al.
American Journal of Hematology|May 29, 2025
Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is UndefinedRuben Van Dijck, Zoran Erjavec, John-John B Schnog
British Journal of Haematology|April 24, 2026
A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myelomaJohn-John B Schnog, Zoran Erjavec, Ruben Van Dijck
Nederlands Tijdschrift Voor Geneeskunde|October 27, 2022
[Financial conflict of interest and anti-cancer drugs: Why the NTVG's stance to exclude pharma-advertisement is of importance.]John-John B Schnog, Michael J Samson, Ashley J Duits
The New England Journal of Medicine|September 21, 2022
Trastuzumab Deruxtecan in HER2-Low Breast CancerJohn-John B Schnog, Michael J Samson, Ashley J Duits
British Journal of Haematology|January 12, 2023
An analytical view of the BJH publication of 'a clinician's view of voxelotor'John-John B Schnog, Michael J Samson, Ashley J Duits
Lancet Regional Health. Americas|February 13, 2023
Contemporary oncology trials, drug approvals and the physician-patient relationshipJohn-John B Schnog, Michael J Samson, Ashley J Duits
Cancer|February 6, 2025
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?Bart M F Penninx, Michael J Samson, John-John B Schnog
American Journal of Hematology|December 24, 2009
Letter in response to: "Pulmonary thrombi are not detected by 3D magnetic resonance angiography in adults with sickle cell anemia and an elevated triscuspid regurgitant jet velocity"Eduard J Van Beers, Bart J Biemond, John-John B Schnog, et al.
Pageof 4